# Centogene N.V.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/centogene-n-v

- Industry: Biotechnology
- Headquarters: Rostock, Germany
- Website: www.centogene.com/
- Total disclosed funding: $28M
- Latest round: Series A (Jun 13, 2017)
- Investors on record: 4

## About

Based in Rostock, Germany, and founded in 2006 and led by CEO David Jiménez, Centogene N.V. operates as a provider of gene testing and drug discovery services for patients with rare diseases. As of 2024, the company is traded in Nasdaq with the ticker symbol CNTG. In November 2024, Charme Capital Partners agreed to fully acquire Centogene GmbH from Centogene N.V. for EUR 8.7 million.

Centogene N.V. offers a variety of diagnostic tests and services, including genetic and multiomic testing, next generation sequencing (NGS) panels, whole exome sequencing (WES), and whole genome sequencing (WGS), covering over 19,000 genes. The company specializes in tests such as mitochondrial disease testing, newborn screening, hereditary cancer testing, and somatic cancer testing. It also offers CentoCloud, a cloud-based bioinformatics SaaS platform for rapid genetic data analysis. As of 2024, the firm operates in various locations including Boston, MA, Berlin, Germany, and Rotkreuz, Switzerland.

## Funding rounds

- Series A, Jun 13, 2017, $28M — TVM Capital Life Science, Deutsche Private Equity, CIC Capital, Careventures

## Investors

- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series A
- Deutsche Private Equity (https://capitalatlas.ai/funds/deutsche-private-equity) — Series A
- CIC Capital — Series A
- Careventures (https://capitalatlas.ai/funds/careventures) — Series A